In order to optimize therapeutic success, we combine approaches that target the tumor cells, the tumor microenvironment, and the innate and adaptive immune system. Innovative new molecules targeting the multi-faceted approach of the cancer disease process may also be suitable for use in combination with established standard cancer therapies. By using our established strengths in cancer pharmacology, signal transduction, angiogenesis, as well as immunotherapy/vaccination, we currently have several projects in our R&D pipeline addressing unmet needs in a range of cancers. For these approaches, we build upon expertise in both small molecules and biologics.Neurodegenerative Diseases
In order to develop new therapeutic options for patients, we conduct extensive research to expand our expertise in Multiple Sclerosis (MS) and build research expertise in Parkinson’s disease (PD) and Alzheimer’s Disease (AD). Our longstanding experience in MS provides a solid base upon which we build to study breakthrough solutions in other neurodegenerative diseases. Our strength in immunomodulation and neurobiology research gives a strong foothold into novel therapeutic approaches for improved symptomic treatment and for the development of disease modifying therapies.Rheumatology
Our strength in biotherapeutics and immune-based therapies gives rich possibilities for novel therapeutic approaches in major areas of unmet medical needs. Our research focuses on drugs that modulate key pathogenic mechanisms in rheumatologic diseases. We combine approaches that target T- and B-cell biology, cytokines & chemokines pathways, as well as tissue biology / repair mechanisms, in order to provide better drugs with improved efficacy, safety, and convenience. We currently have innovative projects in our R&D pipeline that may provide new therapies for diseases such as systemic lupuserythematosus (SLE), rheumatoid arthritis (RA), and osteoarthritis (OA).Fertility
Infertility and reproductive health are historical strengths of our company and remain areas of focus. We explore new technologies to increase the success rates of in vitro fertilization treatments and aim to develop new biotherapeutics within the areas of ovulation induction and assisted reproduction.